

ASX:NRT
NASDAQ:NVGN

Novogen Ltd
(Company)

ABN 37 063 259 754

Capital Structure

Ordinary Shares on
issue:

450M

Board of Directors

Mr John O'Connor
Chairman
Non-Executive Director

Mr Bryce Carmine
Deputy Chairman
Non-Executive Director

Dr James Garner
Chief Executive Officer
Managing Director

Mr Ian Phillips MNZM
Non-Executive Director

Mr Iain Ross
Non-Executive Director

Mr Steven Coffey
Non-Executive Director

MARKET RELEASE

26 October 2016

NOVOGEN PRESENTS AT AUSBIOTECH CONFERENCE

Sydney, 26th October 2016 – Australian oncology-focused biotechnology company Novogen Ltd (ASX: NRT; NASDAQ: NVGN) is pleased to release the presentation that CEO, Dr James Garner will be presenting at the AusBiotech Conference 2016 being held in Melbourne, Australia.

Dr James Garner will be presenting today in Melbourne at the Melbourne Convention Centre at 10:05 am, AEDT.

[ENDS]

Media and Investor Relations	Investor Relations (US)
Glen Zurcher E: glen.zurcher@irdepartment.com.au T: +61 420 249 299	Robert Kennedy E: robert.kennedy@novogen.com T: +1 212 519 9832 / +1 646 662 3574

About Novogen Limited

Novogen Limited (ASX: NRT; NASDAQ: NVGN) is an oncology-focused biotechnology company based in Sydney, Australia. Novogen has two proprietary drug discovery platforms (superbenzopyrans and anti-tropomyosins) with the potential to yield first-in-class agents across a range of oncology indications. The three lead molecules Cantrixil, Anisina, and Trilexium are in preclinical development, with the most advanced molecule, Cantrixil, slated to enter clinical trials in late 2016. For more information, please visit: www.novogen.com



Novogen Limited

Presentation to Australia Biotech Invest Annual Conference

Dr James Garner
Chief Executive Officer
james.garner@novogen.com

Melbourne, VIC
26th October 2016

Forward-Looking Statements

This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual results of the Company to differ materially from the results expressed or implied by such statements, including changes from anticipated levels of customer acceptance of existing and new products and services and other factors. Accordingly, although the Company believes that the expectations reflected in such forward-looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. The Company has no obligation to sales, future international, national or regional economic and competitive conditions, changes in relationships with customers, access to capital, difficulties in developing and marketing new products and services, marketing existing products and services update the forward-looking information contained in this presentation.

Novogen is a biotech company dedicated to driving sustainable, long-term growth in shareholder value

Focus on unmet medical need

Pipeline of novel therapies, targeting oncology patients poorly served by existing treatment options

Financially sound

Listed on ASX and NASDAQ, with cash runway sufficient to drive existing pipeline for at least two years


Clinical stage

Lead molecule entering phase I in Q4 2016, with substantial flow of value-driving milestones over 12-18 months

Strong management and Board

Lean team of internationally-experienced pharma executives, overseen by seasoned Board

Novogen is listed on ASX and NASDAQ (via ADRs) and is well-funded for current operations



Market Capitalisation

AU\$ 41 million

Listing

ASX: NRT
NASDAQ: NVGN (1:25 ratio)

Average Daily Volume

ASX: ~570,000 /day
NASDAQ: ~50,000 ADRs /day

Shares on Issue


450 million
(40% US, 60% Australia)

Outstanding Options / Warrants


74 million

Cash at Bank
US\$ 25 million

Novogen is oncology-focused, with a robust in-house pipeline and strong partnering aspirations



Novogen is configured for efficient and effective drug development



- Rationalisation of portfolio to focus on three most advanced oncology opportunities; deprioritization of early stage rare diseases program
- Addition of internationally-experienced pharma executives to team
- Establishment of Scientific Advisory Board
- Development of rigorous GxP quality systems
- Rationalisation of corporate structure and governance

Novogen has a strong management team with international experience in big pharma



Dr James Garner

Chief Executive Officer & Managing Director

Physician / MBA; Extensive pharma drug development experience



Dr David Brown

Chief Scientific Officer

Twenty years of drug discovery and development experience



Dr Gordon Hirsch

Chief Medical Officer

Physician / MBA; Twenty years of pharmaceutical industry experience



Dr Peng Leong

Chief Business Officer

Eighteen years of business development and investment banking experience



Dr Andrew Heaton

VP, Drug Discovery

Twenty years of medicinal chemistry experience




Cristyn Humphreys

Chief Financial Officer

Chartered accountant with twenty years of experience in corporate roles

Novogen's pipeline includes three molecules, with two entering the clinic over the next nine months

ATM Platform	First-in-class program targeting cancer-specific tropomyosin isoform in cytoskeletal microfilaments of cancer cells, leading to apoptosis
SBP Platform	First-in-class program based on earlier clinically-validated isoflavone chemotype (e.g. phenoxidiol, MEI Pharma), but with distinct IP space and greater preclinical activity



Novogen anticipates a rich news flow of value-driving events over the next 12-18 months

Key Milestones		
1Q 2016	Granting of patent for SBP technology	✓
2Q 2016	Granting of patent for ATM technology	✓
3Q 2016	Submission of IND for Cantrixil	✓
4Q 2016	Start of phase I trial for Cantrixil	
2017	Submission of IND for Anisina	
2017	Start of phase I trial for Anisina	



